Atazanavir Sulfate. Fresh from the Pipeline

Aarti Raja; J. Lebbos; P. Kirkpatrick

Atazanavir Sulfate. Fresh from the Pipeline

Aarti Raja
, J. Lebbos
, P. Kirkpatrick

Department of Biological Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

In June 2003, atazanavir sulphate (Reyataz; Bristol-Myers Squibb) — the first once-daily HIV-1 protease inhibitor — was approved by the US FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents. Will its favorable dosing schedule and side-effect profile lead to success in this crowded and complex market?

Original language	American English
Journal	Nature Reviews Drug Discovery
State	Published - Nov 1 2003

Disciplines

Biology

Access to Document

https://www.nature.com/articles/nrd1232?platform=hootsuite#Sec1

Cite this

@article{6aac34eb83d74aa88b88901323a99430,

title = "Atazanavir Sulfate. Fresh from the Pipeline",

abstract = " In June 2003, atazanavir sulphate (Reyataz; Bristol-Myers Squibb) — the first once-daily HIV-1 protease inhibitor — was approved by the US FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents. Will its favorable dosing schedule and side-effect profile lead to success in this crowded and complex market?",

author = "Aarti Raja and J. Lebbos and P. Kirkpatrick",

year = "2003",

month = nov,

day = "1",

language = "American English",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Research",

}

TY - JOUR

T1 - Atazanavir Sulfate. Fresh from the Pipeline

AU - Raja, Aarti

AU - Lebbos, J.

AU - Kirkpatrick, P.

PY - 2003/11/1

Y1 - 2003/11/1

N2 - In June 2003, atazanavir sulphate (Reyataz; Bristol-Myers Squibb) — the first once-daily HIV-1 protease inhibitor — was approved by the US FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents. Will its favorable dosing schedule and side-effect profile lead to success in this crowded and complex market?

AB - In June 2003, atazanavir sulphate (Reyataz; Bristol-Myers Squibb) — the first once-daily HIV-1 protease inhibitor — was approved by the US FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents. Will its favorable dosing schedule and side-effect profile lead to success in this crowded and complex market?

UR - https://nsuworks.nova.edu/cnso_bio_facarticles/69

UR - https://www.nature.com/articles/nrd1232?platform=hootsuite#Sec1

M3 - Article

SN - 1474-1776

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

ER -

Atazanavir Sulfate. Fresh from the Pipeline

Abstract

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this